Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the North Central Cancer Treatment Group

Journal of Clinical Oncology

Volumn 23, Issue 6, 2005, Pages 1103-1108

  Witzig, Thomas E ^a   Vukov, Allen M ^a   Habermann, Thomas M ^a   Geyer, Susan ^a   Kurtin, Paul J ^a   Friedenberg, William R ^a   White, William L ^a   Chalchal, Haji I ^a   Flynn, Patrick J ^a   Fitch, Thomas R ^a   Welker, Debra A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; LACTATE DEHYDROGENASE; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLEEDING; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MAINTENANCE THERAPY; MALE; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; REMISSION; TREATMENT OUTCOME; TREATMENT RESPONSE; URTICARIA; B CELL LYMPHOMA; CHEMICALLY INDUCED DISORDER; DISEASE FREE SURVIVAL; FOLLICULAR LYMPHOMA; MIDDLE AGED; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS;

EID: 20044362555     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.12.052     Document Type: Article

References (26)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998
2. Feuring-Buske M, Kneba M, Unterhalt M, et al: IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced- stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79:493-500, 2000
3. Foran JM, Gupta RK, Cunningham D, et al: A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109:81-88, 2000
4. Ghielmini M, Schmitz SF, Burki K, et al: The effect of Rituximab on patients with follicular and mantle-cell lymphoma: Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 11:123-126, 2000
5. Igarashi T, Kobayashi Y, Ogura M, et al: Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study. Ann Oncol 13:928-943, 2002
6. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188-2195, 1997
7. Nguyen DT, Amess JA, Doughty H, et al: IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients. Eur J Haematol 62:76-82, 1999
8. Igarashi T, Ohtsu T, Fujii H, et al: Retreatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 73:213-221, 2001
9. Davis TA, Grillo-Lopez AJ, White CA, et al: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment. J Clin Oncol 18:3135-3143, 2000
10. Koh LP, Lim LC, Thng CH: Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 17:225-228, 2000
11. Buckstein R, Imrie K, Spaner D, et al: Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 26:115-122, 1999
12. Flinn IW, O'Donnell PV, Goodrich A, et al: Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 6:628-632, 2000
13. Magni M, Di Nicola M, Devizzi L, et al: Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion. Blood 96:864-869, 2000
14. Cheson B, Horning S, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 17:1244-1253, 1999
15. Duffy D, Santner T: Confidence intervals for a binomial parameter based on multistage tests. Biometrics 43:81-93, 1987
16. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 53:457-481, 1958
17. Travis LB, Curtis RE, Glimelius B, et al: Second cancers among long-term survivors of non-Hodgkin's lymphoma. J Natl Cancer Inst 85:1932-1937, 1993
18. Travis LB, Curtis RE, Stovall M, et al: Risk of leukemia following treatment for non-Hodgkin's lymphoma. J Natl Cancer Inst 86:1450-1457,1994
19. Kyle RA, Greipp PR, Gertz MA, et al: Waldenstrom's macroglobulinaemia: A prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 108:737-742, 2000
20. Micallef IN, Apostolidis J, Rohatiner AZ, et al: Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 1:367-373, 2000
21. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
22. Johnson P, Rohatiner A, Whelan J, et al: Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center. J Clin Oncol 13:140-147, 1995
23. Cabanillas F: Can we cure indolent lymphomas? Clin Cancer Res 3:2655-2659, 1997
24. Colombat P, Salles G, Brousse N, et al: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood 97:101-106, 2001
25. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002
26. Hainsworth JD, Litchy S, Morrissey L, et al: Rituximab as first-line and maintenance therapy for indolent non-Hodgkin's lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trial. Blood 102, 2003 (abstr 1496)